Navigation Links
Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
Date:4/1/2008

BZL101 selectively kills cancer cells but not normal cells

EMERYVILLE, Calif., April 1 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) today announced the publication of a peer-reviewed article in the journal Cancer Biology and Therapy that elucidates the molecular mechanisms underlying selective cytotoxic activity of BZL101, the company's drug for advanced breast cancer.

"BZL101 induces cell death in breast cancer cells but not in normal breast cells," said Emma Shtivelman, Ph.D., Director of Cancer Research at Bionovo. "This selective cell killing is based on strong induction by BZL101 of reactive oxygen species (ROS) in tumor cells. The ROS cause extensive DNA damage in tumor cells but not in normal cells, which then leads to the inhibition of glycolysis selectively in tumor cells. This action is most clearly evident from the decrease in the enzymatic activities within the glycolytic pathway and the inhibition of lactate production. The observed inhibition of glycolysis is a key factor in the energetic collapse and death that occurs selectively in breast cancer cells, 'selectively' because tumor cells rely on glycolysis for energy production."

Separately, Isaac Cohen, O.M.D., Bionovo's Chairman and CEO, stated, "The promising selectivity of BZL101 towards cancer cells is based on metabolic differences between highly glycolytic tumor cells and normal cells. Coupled with promising clinical development, BZL101 has the potential to be an important treatment for women with breast cancer, as well as potentially for other cancers. BZL101 could fill an important unmet medical need in cancer treatment."

About BZL101

BZL101 is an oral drug designed for the treatment of advanced breast cancer and pancreatic cancer with a novel mechanism of action. BZL101 targets cancer cells while leaving normal cells healthy and intact. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. In contrast, cancer cells depend largely on glycolysis (>85%) for energy production. BZL101 leads to energy collapse in cancer cells by inhibiting glycolysis. This leads to DNA damage and cell death in cancer cells while normal cells remain unharmed.

BZL101 has completed early stage clinical testing conducted at the University of California, San Francisco and the Cancer Research Network in Plantation, Florida. Data from the Phase 1 trial of BZL101 indicate that BZL101 has a favorable tolerability profile and demonstrates encouraging clinical activity in a heavily pretreated population. BZL101 is currently undergoing Phase 1/2 clinical testing for late stage metastatic breast cancer. Visit http://www.bzl101.com to find out more about BZL101.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
3. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
4. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
5. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
6. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):